Neoleukin Therapeutics, Inc. appointed Donna M. Cochener as the Company's Interim Chief Executive Officer and designated her as the Company's principal executive officer each effective as of March 31, 2023 . The Executive Officer Appointments occurred in connection with Dr. Jonathan Drachman, M.D.'s resignation from his role as President, Chief Executive Officer, principal executive and financial officer and director of the Company as of the Effective Date, as previously announced on March 6, 2023. Prior to her appointment as the Company's Interim Chief Executive Officer and designation as the Company's principal executive officer, Ms. Cochener, age 48, served as the Company's General Counsel, Senior Vice President Legal since March 2022.

Before joining the Company, Ms. Cochener was Senior Vice President, Deputy General Counsel of HomeStreet, Inc., a financial services holding company, and its wholly owned subsidiary, HomeStreet Bank, from February 2016 to November 2021. Prior to joining HomeStreet Bank, Ms. Cochener was a Partner at Davis Wright Tremaine, LLP, a law firm, in Seattle, Washington. She has also served as Chairman of the Board of Cochener Garvey Capital Partners, Inc. and its affiliated subsidiaries since August 2012.

Ms. Cochener received a Bachelor of Science in Journalism from Northwestern University and a Juris Doctorate and Masters of Law in International Comparative Law from Duke University.